Ludwig previews Revealia Breast™ cheek-swab test; Q3 2025 launch expected

LUDWIG ENTERPRISES, INC.

Revealia Breast™ uses mRNA biomarkers and AI from a cheek swab for early cancer detection.
Test is in advanced development with expected release in Q3 2025.
Cites ASBS study: 39.7% non-invasive disease vs 13.2% with traditional management.
First in pipeline of non-invasive mRNA-based cancer screening tests targeting major cancers.
No financial data or revenue projections provided in the release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.